Learn what zavegepant is, how this next-generation CGRP receptor antagonist works, and why its fast-acting nasal spray formulation is a game-changer for acute migraine treatment, especially for patients with nausea or vomiting.
Learn what zavegepant is, how this intranasal CGRP receptor antagonist works for acute migraine treatment, and why its non‑vasoconstrictive, needle‑free nasal spray delivery may benefit patients with nausea or cardiovascular risk factors.
Learn what zavegepant is, how this intranasal CGRP receptor antagonist differs from traditional triptans, and review key clinical trial evidence on its speed, effectiveness, and safety for acute migraine treatment.
Learn what zavegepant is, how its intranasal CGRP receptor blockade works, and why it’s emerging as a fast, needle‑free option for acute migraine relief and prevention.
Learn how zavegepant, the first intranasal CGRP receptor antagonist, offers fast-acting, targeted relief for acute migraine—especially for patients who can’t tolerate oral medications or need rapid onset of action.